Gain Therapeutics (Gain Therapeutics) Float Percentage Of Total Shares Outstanding : 93.34% (As of Jun. 06, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Gain Therapeutics's float shares is 16.85 Mil. Gain Therapeutics's total shares outstanding is 18.05 Mil. Gain Therapeutics's float percentage of total shares outstanding is 93.34%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Gain Therapeutics's Insider Ownership is 1.81%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Gain Therapeutics's Institutional Ownership is 1.86%.

Gain Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Gain Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	16.85	/	18.05
	=	93.34%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gain Therapeutics (Gain Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814

Website

https://www.gaintherapeutics.com

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.

Executives

Matthias Alder	officer: Chief Operating Officer	C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne	officer: Chief Financial Officer	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta	officer: Principal Accounting Officer	C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Salvatore Calabrese	officer: Chief Financial Officer	C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Goldstein Dov A Md	director
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Claude Nicaise	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto	officer: President and General Manager	C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814